-
Fucoidan Workflows for Breast Cancer Research
2026-09-15
Build a practical Fucoidan workflow that connects MCF-7 viability, migration, colony formation, and caveolin-1 analysis with orthogonal cancer biology readouts. The approach also shows how to compare a marine sulfated polysaccharide with tamoxifen while controlling solubility, vehicle, and assay-specific artifacts.
-
SERF as a Modifier of Amyloid Formation
2026-09-14
The dissertation “SERF is a modifier of amyloid formation” examines how SERF/MOAG-4 influences amyloid biology through complementary yeast, molecular, and protein-biochemical approaches. Its main contribution is to position SERF as a regulatory modifier of amyloid formation and to connect genetic perturbation with biochemical analysis of soluble and insoluble protein states.
-
WST-8 Glucose Uptake Assay: Readout and Design
2026-09-14
The WST-8 Glucose Uptake Assay Kit provides a non-radioactive, colorimetric route to quantify cellular glucose uptake. This article explains how to interpret the redox-linked signal, design controls for ion-modulated transfection studies, and distinguish transport from downstream metabolic effects.
-
Chenodeoxycholic Acid: From FXR Ligand to Assay
2026-09-13
Chenodeoxycholic Acid is more than a bile acid metabolism reagent: it is a mechanistic probe for connecting FXR transcriptional activity with inflammatory and injury phenotypes. This guide translates recent FXR–KLF11 findings into practical assay design, controls, and interpretation strategies.
-
GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer
2026-09-12
The reference study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and promotes malignant behavior in bladder cancer cells. Its combination of public-data analysis, RNA sequencing, chromatin immunoprecipitation, genetic perturbation, and drug-sensitization experiments provides a mechanistic framework for studying GLI2-dependent cisplatin resistance.
-
Metoprolol Tartrate in β1 Cardiovascular Research
2026-09-11
Metoprolol Tartrate is a selective β1-adrenergic blocking agent for cardiovascular research involving heart rate, contractility, hypertension, angina, and arrhythmia biology. A recent mouse and human hematopoietic cell transplant study found that β1-selective metoprolol did not reproduce the engraftment impairment associated with nonselective β-blockade.
-
Metoprolol Tartrate for β1-Selective Research
2026-09-11
Metoprolol Tartrate enables controlled β1-adrenergic receptor inhibition in cardiomyocyte, vascular, and transplantation-related assays. Its selectivity provides a practical contrast with nonselective β-blockade, helping researchers separate cardiac receptor effects from β2/β3-dependent regenerative pathways.
-
Neomycin Sulfate for RNA/DNA Assays
2026-09-10
Neomycin sulfate is an aminoglycoside antibiotic that serves as a mechanistic probe for ribozyme catalysis, HIV-1 Tat–TAR recognition, DNA triplexes, and ryanodine receptor currents. This guide translates its binding and channel effects into practical assay workflows while showing how to avoid confounding antibiotic, ionic-strength, and storage variables.
-
Mubritinib (TAK 165): Complex I Assay Workflows
2026-09-10
Mubritinib (TAK 165) enables mechanism-led studies of mitochondrial complex I inhibition in chemotherapy-resistant AML and KSHV-positive primary effusion lymphoma. This workflow-focused guide separates OXPHOS effects from HER2 biology and provides practical dosing, assay-selection, and troubleshooting strategies.
-
Trichostatin A: Reading HDAC Biology Beyond Histones
2026-09-09
Trichostatin A (TSA) is more than a tool for inducing histone hyperacetylation. This article connects TSA assay design with emerging evidence on HDAC6-regulated tubulin lactylation, showing how orthogonal readouts can sharpen cancer and differentiation research.
-
Tubastatin A: Interpreting HDAC6-Linked Injury
2026-09-09
Tubastatin A is a selective HDAC6 inhibitor whose value extends beyond target potency. This article explains how to connect HDAC6 engagement with microtubule, inflammatory, and programmed-cell-death readouts while translating porcine cardiac-arrest evidence into better experimental decisions.
-
SmD2 Acetylation Links Splicing to PARP Response in HCC
2026-09-08
The reference study identifies SmD2 acetylation as a regulatory connection between core spliceosome activity, BRCA1/FANC cassette-exon selection, DNA-damage repair, and PARP-inhibitor sensitivity in hepatocellular carcinoma. Its findings support a combination strategy in which HDAC inhibition is used to alter SmD2 stability and improve responses to PARP inhibition, although validation in additional tumor contexts remains necessary.
-
How Early Pheromones Accelerate Neurodegeneration
2026-09-08
Peng et al. show that exposure to the C. elegans pheromones ascr#3 and ascr#10 during the L1 stage remodels neural development and increases neurodegeneration in adulthood. The study defines a circuit linking ASK and ASI chemosensory neurons to AIA interneurons, insulin-like signaling, and neuronal autophagy, providing a mechanistic framework for how early environmental cues can influence later proteostasis.
-
EZ Cap™ OVA mRNA for Immune Research
2026-09-07
EZ Cap™ OVA mRNA provides a standardized ovalbumin antigen source for immune response immunogen studies, airway hyperreactivity models, gene expression studies, and vaccine development research. Its Cap 1 structure, poly(A) tail, and defined handling workflow also make it a practical tool for comparing mRNA delivery systems while monitoring expression and inflammatory effects.
-
PP 3: A Better Control for Src Signaling Translation
2026-09-07
Translational studies often overinterpret inhibitor-sensitive phenotypes when scaffold, vehicle, and pathway effects are not separated. This thought-leadership article explains how PP 3, a research use only chemical and negative control for PP 2, can strengthen Src kinase signaling pathway research while connecting vascular ROS biology to more rigorous experimental design.